Send to

Choose Destination
See comment in PubMed Commons below
Agents Actions Suppl. 1992;38 ( Pt 3):110-8.

The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors.

Author information

Department of Pharmacology/Clinical Pharmacology, University of Groningen, The Netherlands.


Bradykinin plays a role in the regulation of coronary blood flow. Under basic conditions the vasodilating effect is primarily mediated by stimulation of the endogenous nitrovasodilator endothelium-derived relaxing factor (EDRF). This effect is shortlasting but can be increased and prolonged by sulfhydryl(SH)-containing agents. ACE-inhibitors may cause coronary vasorelaxation by a bradykinin-mediated release of EDRF. This can be potentiated by the presence of SH-groups, as was shown with captopril and zofenoprilat. As a consequence, SH-containing ACE-inhibitors may potentiate nitrates, because they act as exogenous nitrovasodilators, and reverse tolerance to their therapeutic effect.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center